Delivery Order SPE2DB20D2104-SPE2DB23FS64T
- Not listed
- This federal contract award, valued at $1,039.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,560,830,894 units of Naloxone HCL 4 mg Nasal Spray 2S, a critical medication used to treat opioid overdoses. The contract is a Delivery Order with a Firm Fixed Price, with a completion date of May 5, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) valued at...
- This federal contract award, valued at $1,838.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,999,320 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This delivery order contract has a firm fixed-price pricing type and an ultimate completion date of April 23, 2025. Amerisourcebergen Drug Corp also...
- This federal contract award, valued at $1,211.88, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,566,450,464 units of Naloxone HCL 4 mg Nasal Spray, with an ultimate completion date of November 18, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued...
- This federal contract award, valued at $2,428.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,558,996,786 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. The contract has an ultimate completion date of November 7, 2022 and is a Delivery Order (DO) contract type with a Firm Fixed Price pricing structure. The award is not designated as a...
- This federal contract award, valued at $5,684.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,874,751 units of Naloxone HCL 4 mg Nasal Spray 2s, a critical medication used to treat opioid overdoses. The contract is a delivery order, with a firm fixed price pricing type, and an ultimate completion date of April 11, 2025. It is not designated as a...
- This federal contract award, valued at $2,782.09, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,561,182,545 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This is a firm fixed-price delivery order with a completion date of June 9, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a...
- This federal contract award, valued at $7,744.93, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,564,861,499 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. The contract has an ultimate completion date of June 11, 2024 and is a firm fixed-price delivery order. AmerisourceBergen holds a significant Indefinite...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,562,549,272 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. The contract has a total ceiling value of $3,275.59 and a completion date of October 23, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- This federal contract award, valued at $1,405.89, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the procurement of 4,567,316,980 units of 4 mg naloxone HCl nasal spray. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a...
- This federal contract award, valued at $2,037.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order for 4,568,161,333 units of Naloxone HCl 4 mg Nasal Spray, a medication used to treat opioid overdose. The contract has a firm fixed-price pricing type and an ultimate completion date of May 7, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FS64TDelivery Order
This federal contract award, valued at $2,725.41, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,560,286,425 units of Naloxone HCl 4 mg Nasal Spray, a critical drug used to reverse opioid overdoses. The contract has a firm fixed price and an ultimate completion date of March 17, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. This contract award demonstrates AmerisourceBergen's role as a key vendor for the DLA and other federal agencies in supplying essential medical commodities, including specialty medications, brand-name and generic drugs, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 3/16/23 |